Scientific article
OA Policy
English

Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine : Immune Correlates in Long-Term Survivors

Published in

Biomedicines, vol. 13, no. 5, 1122

Publication date

2025-05-06

First online date

2025-05-06

Abstract

Background: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. Clinical trials in advanced cancer patients have demonstrated low toxicity, high immunogenicity and clinical benefit. The goal of this study was to identify circulating biomarkers of clinical outcome.

Methods: Eighteen patients with stage IIIb/IV non-small-cell lung cancer (NSCLC) were injected with racotumomab-alum as switch maintenance therapy after first-line chemotherapy. Treatment was administered until severe performance status worsening or toxicity. The frequencies of innate and adaptive lymphocytes were assessed by flow cytometry. Circulating factors were measured using multi-analyte flow assay kits.

Results: The median overall survival was 16.5 months. Twenty-seven percent of patients were classified as long-term survivors. Patients with lower baseline frequencies of CD4+Tregs and central memory (CM) CD8+T cells displayed longer survival rates. Furthermore, higher baseline frequencies of NKT cells and a high CD8+T/CD4+Treg ratio were associated with longer survival. Interestingly, patients with significantly lower levels of effector memory (EM) CD8+T cells survived longer. The levels of NKT cells and terminal effector memory (EMRA) CD8+T cells were higher in long-term survivors in comparison with short-term survivors in post-immune samples. As expected, the ratio of CD8+T/CD4+Tregs showed significantly higher values during treatment in patients with clinical benefits. Regarding serum factors, pro-tumorigenic cytokines significantly increased during treatment in poor survivors.

Conclusions : In advanced NSCLC patients receiving racotumomab-alum vaccine, longer survival could be associated with a unique profile of circulating lymphocyte subsets at baseline and during treatment. Additionally, certain pro-tumor-related cytokines increased in short-term survivors. These results should be confirmed in larger randomized clinical trials. This clinical trial was registered in the Cuban Clinical Trials Register (RPCE00000279).

Keywords

  • Anti-idiotypic cancer vaccine
  • Circulating biomarkers
  • Non-small cell lung cancer

Citation (ISO format)

MAZORRA, Zaima et al. Treatment of Advanced NSCLC Patients with an Anti-Idiotypic NeuGcGM3-Based Vaccine : Immune Correlates in Long-Term Survivors. In: Biomedicines, 2025, vol. 13, n° 5, p. 1122. doi: 10.3390/biomedicines13051122

Main files (1)

Article (Published version)

Secondary files (1)

Appendix

Identifiers

Additional URL for this publication

https://www.mdpi.com/2227-9059/13/5/1122

Journal ISSN

2227-9059
44views
82downloads

Technical informations

Creation

02/07/2025 13:57:54

First validation

04/07/2025 09:45:22

Update

13/10/2025 11:35:40

Status update

04/07/2025 09:45:22

Last indexation

21/10/2026 07:38:44
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated